Dr Benjamin Weinberg from the Lombardi Comprehensive Cancer in Washington, DC, discusses key studies from the ASCO 2020 virtual meeting for patients with metastatic colorectal cancer (mCRC).
The KEYNOTE-177 trial, presented at the plenary session, establishes a new standard of care for MSI-H mCRC patients. In this trial, PFS was improved by 8.3 months when pembrolizumab versus chemotherapy was used in the front-line setting.
The DESTINY-CRC01 trial looked at trastuzumab deruxtecan, an antibody–drug conjugate, in refractory HER2-expressing mCRC patients. The trial demonstrated an impressive response rate, which will require further studies.
The RAPIDO trial showed that a short course of radiation is similar to the traditional 5.5 weeks of chemoradiation in patients with high-risk, locally advanced rectal cancer. The trial data suggest radiation alone may be superior to chemoradiation in several measures, including complete pathological response rate. Dr Weinberg comments that these results mark a new standard of care.
Finally, Dr Weinburg discusses two additional presentations that answer critical questions regarding duration of adjuvant chemotherapy and whether chemotherapy after resection of liver metastases provides survival benefit.
Medscape © 2020 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Colorectal Cancer Highlights from ASCO 2020 - Medscape - Jun 24, 2020.
Comments